Lumos Diagnostics Launches Securities Purchase Plan to Issue New Shares and Options

Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has issued an announcement.

Lumos Diagnostics Holdings Ltd., an ASX-listed diagnostics company, has outlined plans to issue new ordinary fully paid shares and unlisted options as part of a securities purchase plan for eligible investors. The proposed capital raising, structured under ASX Listing Rule Appendix 3B, will see up to 8,888,889 new ordinary shares and 4,444,444 unlisted options offered, with a record date of 26 March 2026 and an issue date scheduled for 1 May 2026, potentially strengthening the company’s balance sheet and shareholder base.

The securities purchase plan is expected to run through to a closing date of 24 April 2026, giving existing shareholders the opportunity to increase their holdings on set terms determined by the board. By opting for this form of equity issuance rather than alternative funding channels, Lumos signals a preference for tapping existing investors, which may dilute current shareholdings but could provide additional capital to support its ongoing operations and strategic initiatives in the diagnostics sector.

The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.25 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.

More about Lumos Diagnostics Holdings Ltd.

Lumos Diagnostics Holdings Ltd. is a medical diagnostics company listed on the ASX under the code LDX. The company develops and commercialises diagnostic solutions, with its ordinary fully paid shares forming the primary listed equity securities available to investors in the Australian market.

Average Trading Volume: 3,924,009

Technical Sentiment Signal: Buy

Current Market Cap: A$211.4M

Learn more about LDX stock on TipRanks’ Stock Analysis page.